Skip to content

Effect of ulinastatin on morphine consumption and postoperative adverse reactions during analgesia after hip replacement in elderly patients

Effect of ulinastatin on morphine consumption and postoperative adverse reactions during analgesia after hip replacement in elderly patients

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500097826
Enrollment
Unknown
Registered
2025-02-26
Start date
2024-05-12
Completion date
Unknown
Last updated
2025-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain after hip replacement surgery

Interventions

Control group:Flurbiprofen axidate group was given 100mg flurbiprofen axidate 15min before operation
Test group 1:Ulinastatin 10IU group was given 10IU ulinastatin 15min before operation
Test group 2:Ulinastatin 20IU group was given 20IU of ulinastatin 15min before operation

Sponsors

Tianjin Jizhou District People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
60 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Patients >=60 years of age who need total/semi-hip replacement 2. Awake and able to understand the VAS score 3.ASA is graded from ? to ? 4. Patients who signed a written informed consent for the study

Exclusion criteria

Exclusion criteria: 1. Patients with neuropathic pain (such as tumor pressing on nerve stem, plexus, spinal cord) who are using or are considered by their doctor to need antipanic or antidepressants; Analgesics other than the study drug are being used or are considered necessary by a doctor; 2. There are unstable diseases such as digestive tract ulcers; Or patients with dysfunction of vital organs; 3. Patients with a known allergy to opioids; 4. Patients who are likely to change their concomitant medications (other than those treating adverse opioid reactions) during the study period; 5. According to the judgment of the investigator, patients who are not suitable to participate in this study for any reason other than the inclusion criteria and exclusion criteria.

Design outcomes

Primary

MeasureTime frame
Morphine consumption;The occurrence of postoperative adverse reactions;

Secondary

MeasureTime frame
Pain score (VAS 0-10);Pain and inflammatory factors: bradykinin, IL-6 and IL-8;Liver and kidney function: creatinine, transaminase;

Countries

China

Contacts

Public ContactYan Li

Tianjin Jizhou District People's Hospital

2508016048@qq.com+86 156 0019 4996

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026